Expert in interdisciplinary research across cardiovascular, metabolic, and genetic diseases, with a proven track record of driving innovation and high-impact scientific discoveries. My work focuses on advancing therapeutic strategies for cardiovascular, metabolic, and genetic diseases**. With over 5 years of high-level research experience in Biochemistry, Pharmacology, and Physiology, I lead interdisciplinary investigations that bridge the gap between fundamental science and clinical applications. Beyond my technical contributions, I am a dedicated **mentor to scientific trainees**, fostering collaborative environments that drive innovation in complex biomedical challenges.

Download Full CV (PDF)   ORCID iD Profile

---

Strategic Research Impact

"By bridging molecular biochemistry with physiological clinical applications, my work aims to decode the underlying mechanisms of metabolic disorders, providing the scientific foundation for next-generation therapeutic interventions."

Peer-Reviewed Publications

• Simpson, D., Botta, E. E., et al. (2026). "13-HODE and 13-HOTrE, present in a Traditional Chinese Medicine herbal extract dì gǔ pí, selectively mediates platelet function." Pharmaceuticals. (Accepted Jan 30, 2026).

• Botta, E. E., Pierini, F., et al. (2025). "Modifications on lipid profile and HDL-associated enzymes related to treatment with tofacitinib in patients with rheumatoid arthritis." Journal of Clinical Lipidology, 19(3):659-669. PMID: 40133148.

• Yamaguchi, A., Botta, E., & Holinstat, M. (2022). "Eicosanoids in inflammation in the blood and the vessel." Frontiers in Pharmacology, 13, 997403. PMID: 36238558.

• Martin, M., Gaete, L., ..., Botta, E. E., et al. (2022). "Vascular inflammation and impaired reverse cholesterol transport and lipid metabolism in obese children and adolescents." NMCD, 32(1), 258–268. PMID: 34895801.

• Pierini, F. S., Botta, E., et al. (2021). "Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis." Rheumatology and Therapy, 8(2), 803–815. PMID: 33811316.

• Chiappe, E. L., Martin, M., ..., Botta, E., et al. (2021). "Effect of Roux-en-Y Gastric Bypass on Lipoprotein Metabolism and Markers of HDL Functionality in Morbid Obese Patients." Obesity Surgery, 31(3), 1092–1098. PMID: 33128217.

• Botta, E., Meroño, T., et al. (2016). "Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis." Atherosclerosis, 251, 438–444. PMID: 27344073.

• Boero, L., Manavela, M., Botta, E., et al. (2015). "Conditioning factors for high cardiovascular risk in patients with Cushing Syndrome." Endocrine Practice, 21(7), 734–742. PMID: 25786550.

International Conferences & Presentations

• Sharma, D.S.S., Botta, E., et al. (2023). "Non-Enzymatic role of platelet 12-LOX in platelet activation." 65th American Society of Hematology Annual Meeting, San Diego, CA.

• Botta, E. E., et al. (2022). "Delineating the mechanism between 12-LOX function and its protein complex in platelets." 17th International Conference on Bioactive Lipids in Cancer, New Orleans, LA.

• Botta, E. E., et al. (2022). "Herbal extracts as a novel starting point for potential antiplatelet agents." Hemostasis Gordon Research Conference, Waterville Valley, NH.

• Botta, E. E., et al. (2022). "Screening of herbal compounds for potential antiplatelet targets." 18th Midwest Platelet Conference, Ann Arbor, MI.

• Botta, E. E., et al. (2020). "Improvement in the capacity of HDL to acquire free cholesterol associated with anti-inflammatory actions of tofacitinib in patients with RA." 88th EAS Virtual Congress.

• Pierini, F., ..., Botta, E., et al. (2019). "Effect of tocilizumab on HDL and LDL characteristics in patients with Rheumatoid Arthritis." ACR/ARP Annual Meeting, Atlanta, GA.

• Botta, E., et al. (2017). "Possible effect of cholesteryl-ester transfer protein activity on paraoxonase 1 antioxidant function." 21º IUNS International Congress of Nutrition, Buenos Aires.